Midodrine hydrochloride is a vasopressor/antihypotensive agent.
Adverse reactions or quality problems experienced with the use of this Product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax, using the contact information at the bottom of this page.
Midodrine Update: Opening of a public docket
FDA Memo Midrodine Study January 2011(PDF - 80KB)
FDA Proposes Withdrawal of Low Blood Pressure Drug[ARCHIVED]
FDA NEWS RELEASE - 8/16/2010